The Ban Apple Watches Chorus which has been going on due to patent issue is put to rest temporarily as of now. Apple’s legal tussle over patents took a positive turn as a federal court lifted the sales ban imposed by the International Trade Commission (ITC) on two higher-end models of the Apple Watch.
This move allows the resumption of sales that were halted due to an ongoing patent dispute with medical technology firm Masimo.
The ITC had ordered the sales halt in October, citing infringement concerns over specific technologies integral to the blood-oxygen measurement system in Apple’s Series 9 and Ultra 2 watches. The court’s intervention follows Apple’s compliance with the ruling, which led to the abrupt cessation of online sales in the U.S. just days before the Christmas holiday.
Apple swiftly announced the resumption of sales for the two watch models, stating availability on its online store by noon Pacific Time on Thursday. Moreover, these watches will start reappearing in select Apple stores from Wednesday, with wider accessibility anticipated by Saturday.
This isn’t Apple’s first encounter with patent roadblocks regarding its innovative watch technologies. Last year, the ITC ruled against Apple in an intellectual property dispute with AliveCor, concerning the wearable EKG technology.
Ban Apple Watches, No Final Verdict Yet
Despite the Biden administration’s decision not to overturn the ruling, it hasn’t yet directly impacted Apple Watch sales due to another regulatory body’s assessment that AliveCor’s technology isn’t patentable. However, the legal battle on this front remains ongoing.
The complexities surrounding patents in Apple’s quest to integrate medical technology into its watches suggest a potential shift in strategy. Analysts, like Wedbush Securities’ Dan Ives, predict that Apple might consider pursuing licensing deals or even acquiring startups specialized in this field to navigate these patent challenges effectively.
As the legal landscape evolves, the temporary lift of the sales ban provides a momentary reprieve for Apple, allowing the company to resume sales while awaiting the court’s decision on the pending appeal.
This development underscores the intricate balance between innovation, intellectual property, and regulatory hurdles in the tech giant’s journey toward enhancing its smartwatch capabilities.
